Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by floatinketuckyon Feb 16, 2022 6:44am

482 Views

Post# 34432724

BTD is currently based off data backlocking from NOV 29 2021

The data accrued to date for the TLD 1433-2 open label study for the treatment of NMIBC, seems very encouraging, and Theralase may as well be heading towards fulfilling the necessary outcome requirements to apply for a “BTD from the FDA very soon.
Dr. Vera Madzarevic Director Clinical Development & Quality Assurance, Theralase®
_____________________________________________

In accordance with the FDA’s 2018 guidelines to industry, the patients who have achieved a Partial Response (“PR”) are being further assessed via Computerized Tomography (“CT”) scan and/or biopsy of the prostatic urethra to determine if upper tract Urothelial Cell Carcinoma (“UCC”) or prostatic urethra UCC can be detected to allow these patients to be re-categorized as CR.
________________________________________________
In summary, for patients who received the primary optimized Study II Treatment versus the original Study II Treatment (90 days), there is a 5% increase in CR and a 75% decrease in NR.

Quarterly Newsletter 2Q2021 (theralase.com)

The time line of 2022 for BTD is currently based off data backlocking from NOV 29 2021.
And that latest corprate prezzy is based off that data.

Shall the market expect new data may affect the timetable?

Well yes, it already has.. Look at the timetable in the corp prezzy the quarter back.

Yep that copr prezzy date is moving closer to us with the new data releases.
And of course that data is only up till nov 29 2021.

We will get some data updaates in 2022 also.

Yep prolly more data and no quarterly newsletters anymore

So really in short what up is.... the first 12 patients who got the light dose are now being Weighted against new paitents who have been treated at full dose and remaining first 12 patients who revieve 2nd dose at full dose.

--------------------------------------------------------------

Well guys the copr prez you can see is the current.. lol
So if you didnt see the copr prez before you wont know..
hahahahahahhaghahahha

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario